Mesoblast Ltd
Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease
Regenerative medicine company Mesoblast (ASX: MSB) has been granted US Food and Drug Administration (FDA) approval for its Ryoncil therapy to treat children with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The off-the-shelf drug derived from bone marrow has become the first mesenchymal stromal cell therapy on the US market to treat the condition, which can occur […]
Mesoblast receives coveted FDA designation for Revascor heart treatment
Cellular medicines developer Mesoblast (ASX: MSB) is celebrating the granting of new US Food and Drug Administration (FDA) approval for its Revascor heart disease treatment. The FDA has granted its highly-sought rare pediatric disease (RPD) designation for Revascor following submission of results from a randomised, controlled trial in children with hypoplastic left heart syndrome (HLHS). […]
TPG Global bids for InvoCare, Xero culls workforce and Myer posts record half sales
Private equity firm TPG Global has taken advantage of beleaguered funeral services company InvoCare’s (ASX: IVC) lacklustre FY2022 results, with a non-binding cash takeover offer valuing it at $12.64 per share. Under the non-binding indicative offer, which was made on Tuesday, TPG is proposing to give InvoCare shareholders $12.65 cash for each share held. This […]
Can these fallen small cap angels regain their wings?
One of the trickiest aspects of investing is deciding whether a fallen angel will ever fly again. If they do regain their wings, the rewards of buying in at distressed levels can be enormous. But as they impress on newcomers in Masterchef safety briefings, trying to catch a falling knife can be highly injurious. As […]